Ultragenyx Pharmaceutical Inc. (RARE) Stock Price & How to Invest
Last updated November 2026
Short answer
RARE is Ultragenyx Pharmaceutical, a commercial-stage rare-disease biopharma whose approved drugs already generate real revenue while a stack of gene therapies drives the story; two of them, Genglycos for glycogen storage disease type Ia and Fayuvi for Sanfilippo syndrome type A, won FDA approval in August and September 2026. Investing in it means underwriting a still-unprofitable biotech betting that those approvals convert into a 2027 path to profitability, after its GTX-102 Angelman program failed in Phase 3 and the stock fell about 29.9% in 2026 through November 20.
RARE stock price
As of 2026-11-20, Ultragenyx Pharmaceutical Inc. (RARE) last closed at $16.48, down 50.9% over the past year. Over the past 52 weeks it has traded between $12.88 and $36.54.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Ultragenyx Pharmaceutical Inc.'s investor relations page. Walnut is informational, not investment advice.
RARE key stats
At $16.48 on November 20, 2026, Ultragenyx Pharmaceutical Inc. (RARE) has a market cap of $1.7B.
- Market cap
- $1.7B
- P/E (forward)
- 11.5
- Beta
- 0.36
Market cap, P/E and yield are measured at the $16.48 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Ultragenyx Pharmaceutical Inc. (RARE)?
The last two weeks for Ultragenyx Pharmaceutical Inc., as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- RARE closed at $16.48 on November 20, 2026, up 2.5% over the past five trading days (from $16.08).
Ultragenyx Pharmaceutical Inc. filed no current, quarterly or annual report with the SEC in the last two weeks.
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
Ultragenyx Pharmaceutical Inc. (RARE) latest quarter
Ultragenyx Pharmaceutical reported revenue of $173 million for Q3 2026, up 8% from a year earlier (Ultragenyx Pharmaceutical, Nov 3, 2026).
Source: Ultragenyx Q3 2026 results, Nov 3, 2026. Full earnings breakdown
What does Ultragenyx Pharmaceutical Inc. (RARE) do?
Ultragenyx Pharmaceutical (NASDAQ: RARE) develops and sells treatments for rare and ultra-rare genetic diseases, conditions with small patient populations and often no approved therapy. Its commercial base includes Crysvita for X-linked hypophosphatemia (its largest product), Dojolvi for long-chain fatty acid oxidation disorders, Evkeeza, and Mepsevii, which together produced about $673 million of revenue in 2025. The company spans multiple modalities, protein-replacement, small molecule, antisense, and gene therapy, and in 2026 turned two late-stage gene therapies into approved products: Genglycos (DTX401, pariglasgene brecaparvovec) received accelerated approval for glycogen storage disease type Ia in August 2026, and Fayuvi (UX111) was approved in September 2026 for the neurologic manifestations of Sanfilippo syndrome type A (MPS IIIA) in children with preserved neurodevelopmental function, the first FDA-approved treatment for that condition and the company's sixth FDA approval.
The investment picture is that of a growing but still loss-making specialty biotech that has narrowed its bets. Revenue grew roughly 20% in 2025, yet the company posted a net loss of about $575 million as it funds heavy R&D. Q3 2026 (ended September 30, 2026) revenue was about $173 million, up about 8.1% year over year, with a net loss of about $118 million (EPS of -$1.16 versus -$0.75 expected), and TTM revenue is about $730 million. Management reaffirmed 2026 revenue guidance of $730 million to $760 million, which excludes the new launches, including Crysvita at $500 million to $520 million and Dojolvi at $100 million to $110 million. The larger change was in the pipeline: GTX-102 for Angelman syndrome failed to show efficacy in its Phase 3 trial and is being discontinued, which management attributed to too much variation in the control group, and the UX701 Wilson disease gene therapy is also being terminated. Headcount is being cut by about 20%, to roughly 1,000 employees, and the company reaffirmed that it expects full-year GAAP net income and positive operating cash flow in 2027, with R&D below $350 million (down more than 50% from 2025) and SG&A below $375 million. The sale of two priority review vouchers earned by the new approvals, agreed in October 2026 at $210 million and $203 million, is expected to bring about $350 million of net, non-dilutive cash after licensor payments and fees, booked as other income in 2026 and excluded from the 2027 target. Genglycos has begun treating patients, 35 qualified treatment centers were active at the end of October with 40 targeted by year-end, and the company plans to report start forms in early January 2027 but is not guiding launch revenue for several quarters. The shares closed near $16.54 on November 20, 2026, down about 29.9% year to date and 47% over one year, for a market cap near $1.7 billion.
What's driving Ultragenyx Pharmaceutical Inc. (RARE)?
1. New gene therapy launches
Both gene therapies that were under FDA review are now approved: Genglycos (DTX401) for glycogen storage disease type Ia received accelerated approval in August 2026, and Fayuvi (UX111) for Sanfilippo syndrome type A followed in September 2026. Both target diseases with no prior approved therapy, giving Ultragenyx a first-mover position, and each approval produced a priority review voucher that the company agreed to sell in October 2026 for $210 million and $203 million respectively. Fayuvi's European application has been validated by the EMA and, as of November 2026, a UK application is under MHRA review. Genglycos has begun treating patients and 35 treatment centers were qualified by the end of October 2026. How quickly these launches ramp is now the main commercial question, and management is not guiding launch revenue for several quarters.
2. Angelman setback and a narrower pipeline
GTX-102 for Angelman syndrome, once the largest opportunity in the pipeline relative to Ultragenyx's typical ultra-rare markets, failed to prove efficacy in its one-year randomized Phase 3 trial, and the company is discontinuing it; management blamed high variability in the control group across multiple endpoints. Ultragenyx is also terminating the UX701 gene therapy for Wilson disease. The result is a company with fewer binary shots on goal and a story that rests mostly on its six approved products.
3. Growing commercial base
Crysvita, guided to roughly $500 million to $520 million in 2026, anchors a portfolio that management expects to keep growing at a high-single to low-double-digit rate. A steady base business helps fund the pipeline and supports the stated 2027 profitability target. Dojolvi and Evkeeza add incremental, if smaller, contribution.
4. Cost discipline toward profitability
Ultragenyx is cutting about 20% of its workforce, to roughly 1,000 employees, and expects combined 2026 R&D and SG&A to be flat to down low single digits versus 2025, including about $30 million of first-half restructuring charges and about $25 million expected in Q4. For 2027 it guides R&D below $350 million, down more than 50% from 2025, and SG&A below $375 million, and it reaffirmed a goal of GAAP net income and positive operating cash flow that year. Execution on this cost curve is central to the equity story. Analysts expect a profit of about $1.43 per share in 2027 on revenue near $973 million.
What are the risks to Ultragenyx Pharmaceutical Inc. (RARE)?
Ultragenyx remains unprofitable, with a net loss of about $524 million over the trailing twelve months and, per Yahoo Finance, about $266 million of cash against about $1.19 billion of debt as of September 30, 2026, so continued spending or slow launches could pressure the balance sheet and raise dilution or financing risk. The voucher sales (about $350 million net) ease that pressure but are one-time. The GTX-102 Angelman failure showed how severe binary outcomes can be, and with that program and UX701 discontinued, more of the value now rests on the Genglycos and Fayuvi launches, which management is not yet guiding. The Q3 2026 loss of $1.16 per share was well wider than the $0.75 expected. Rare-disease revenue depends on small patient counts, payer reimbursement, and diagnosis rates, all of which can disappoint, which matters more now that two new gene therapies must find patients. The company faces well-capitalized competitors in gene therapy and orphan drugs, including BioMarin, Sarepta, and larger players. Finally, the 2027 profitability target is a management objective, not a guarantee, and could slip; Wedbush cut its target to $22 from $25 after the quarter.
What is the Ultragenyx Pharmaceutical Inc. (RARE) forecast?
20 analysts publish price targets on RARE, averaging $24.80 as of November 2026, or +50.5% against the $16.48 share price on November 20, 2026. The published targets run from $16.00 to $39.00, a wide spread, and the ratings split 10 buy, 11 hold, 0 sell. Over the last six months there have been 6 raises and 5 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.
Read the full RARE forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.
Is RARE a buy or a sell?
We give no verdict on Ultragenyx Pharmaceutical Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. New gene therapy launches. Both gene therapies that were under FDA review are now approved: Genglycos (DTX401) for glycogen storage disease type Ia received accelerated approval in August 2026, and Fayuvi (UX111) for Sanfilippo syndrome type A followed in September 2026. The most optimistic published target, $39.00, assumes this works close to its best case.
The case against. Ultragenyx remains unprofitable, with a net loss of about $524 million over the trailing twelve months and, per Yahoo Finance, about $266 million of cash against about $1.19 billion of debt as of September 30, 2026, so continued spending or slow launches could pressure the balance sheet and raise dilution or financing risk. The most pessimistic target, $16.00, is roughly what RARE is worth if this bites instead.
Read the full bull and bear case on RARE, including what would have to change to break either one. Walnut is not an investment adviser.
Has Ultragenyx Pharmaceutical Inc. (RARE) split its stock?
No. Ultragenyx Pharmaceutical Inc. (RARE) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.
How is Ultragenyx Pharmaceutical Inc. (RARE) valued?
Market cap, P/E and dividend yield at today's price are in the RARE key stats above. The business figures below come from Ultragenyx Pharmaceutical Inc.'s reported results as of November 2026 and change when it next reports.
- Revenue (TTM): ~$730M (2026 guidance $730M-$760M, excluding launches)
- Q3 2026 revenue: ~$173M (up ~8.1% year over year)
- Q3 2026 EPS: ~-$1.16 vs ~-$0.75 expected (net loss ~$118M)
- Net loss (TTM): ~$524M
- Cash vs debt: ~$266M cash, ~$1.19B debt (September 30, 2026), before ~$350M net of voucher sales
As of November 2026: Ultragenyx trades at about 2.3x trailing revenue, a low multiple for a biopharma with six approvals, and has no trailing earnings; the forward P/E near 11.6x rests entirely on the 2027 profit analysts expect. The market is pricing the launch ramp of Genglycos and Fayuvi, a heavy debt load, the loss of the Angelman program and the credibility of the 2027 profitability goal. Analysts expect about $973 million of revenue in 2027 and a mean price target near $25 across 20 analysts, well above the share price.
What themes does Ultragenyx Pharmaceutical Inc. (RARE) fit?
These are the investment theses RARE naturally fits into. Each links to a full theme guide listing every other stock that belongs and the ETFs commonly used as a passive proxy.
Who competes with Ultragenyx Pharmaceutical Inc. (RARE)?
Rare-disease and orphan-drug specialists
BioMarin Pharmaceutical is the closest peer across skeletal and metabolic rare diseases and gene therapy, and its Voxzogo launch is a commercial reference point. These companies compete for the same ultra-rare patient niches and specialist prescribers.
Gene therapy developers
Sarepta Therapeutics and Rocket Pharmaceuticals push competing gene-therapy programs and vectors, sometimes overlapping in indications like Sanfilippo syndrome. Speed to approval and manufacturing capacity are key competitive levers here.
What stocks are similar to Ultragenyx Pharmaceutical Inc. (RARE)?
Other names that sit close to RARE: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in Ultragenyx Pharmaceutical Inc. (RARE)
There are three common ways to get RARE exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so RARE sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where RARE fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on Ultragenyx Pharmaceutical Inc. (RARE)
Ultragenyx is a real, revenue-generating rare-disease company whose valuation now hinges on two gene therapy launches, deep cost cuts and the credibility of a 2027 profitability target, with the Angelman program that was its biggest pipeline swing now discontinued.
More on Ultragenyx Pharmaceutical Inc. (RARE)
Whether RARE is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is RARE a buy or a sell?, and where the stock could go from here in the RARE stock forecast.
For income investors, whether RARE pays a dividend and how the payout looks is covered in does RARE pay a dividend? And to weigh RARE against a peer, read the full side-by-side comparisons: RARE vs BEAM and RARE vs CRSP.
Wondering how RARE fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Ultragenyx Pharmaceutical Inc.
Ask Walnut's AI anything about RARE and see how it fits what you own.
FAQ
What does Ultragenyx do?
+
Ultragenyx develops and commercializes treatments for rare and ultra-rare genetic diseases. Its products are led by Crysvita, and in 2026 it added two gene therapies, Genglycos for glycogen storage disease type Ia and Fayuvi for Sanfilippo syndrome type A, for six FDA approvals in total. It discontinued GTX-102 for Angelman syndrome after a failed Phase 3 trial and is terminating its UX701 Wilson disease program.
Is Ultragenyx profitable?
+
No. As of November 2026 Ultragenyx was not profitable, with a net loss of about $524 million over the trailing twelve months and a Q3 2026 loss of about $118 million. Management reaffirmed a goal of GAAP net income and positive operating cash flow in 2027, backed by R&D cuts of more than 50%, and analysts expect about $1.43 of EPS that year, but that is an objective rather than a certainty.
How much revenue does Ultragenyx generate?
+
Full-year 2025 revenue was about $673 million, roughly 20% growth, and Q3 2026 revenue was about $173 million, up about 8.1% year over year. TTM revenue is about $730 million. The company's 2026 guidance of $730 million to $760 million excludes the new gene therapy launches.
What is Ultragenyx's biggest product?
+
Crysvita, a treatment for X-linked hypophosphatemia, is its largest product, with 2026 revenue guided to roughly $500 million to $520 million. Dojolvi, Evkeeza, and Mepsevii make up the rest of the commercial portfolio.
What are the key catalysts for RARE stock?
+
The 2026 FDA decisions have landed: Genglycos (DTX401) was approved in August and Fayuvi (UX111) in September. The next catalysts are the ramp of those launches (with start forms due to be reported in early January 2027), roughly $350 million of net proceeds from two priority review voucher sales, European and UK review of Fayuvi, delivery of the 2027 cost cuts, and Q4 2026 results in early 2027.
Who competes with Ultragenyx?
+
Peers include rare-disease specialists like BioMarin, gene-therapy developers like Sarepta and Rocket Pharmaceuticals, and larger diversified players such as Sanofi, Takeda, Pfizer, and Novartis that have expanding rare-disease and orphan-drug businesses.
What are the main risks with Ultragenyx?
+
The main risks are continued losses and about $1.19 billion of debt, potential dilution, a launch ramp for two new gene therapies that management is not yet guiding, small rare-disease patient populations, reimbursement pressure, competition, and the possibility that the 2027 profitability target slips. The failed GTX-102 Angelman trial removed one of the biggest pipeline opportunities.
How much cash does Ultragenyx have?
+
Ultragenyx reported about $737 million in cash, cash equivalents, and marketable securities as of December 2025, and Yahoo Finance lists about $266 million of cash against about $1.19 billion of debt as of September 30, 2026. The October 2026 sale of two priority review vouchers for $210 million and $203 million is expected to add about $350 million of net, non-dilutive cash toward its 2027 profitability goal.
How did Ultragenyx do in its latest quarter?
+
For Q3 2026 (ended September 30, 2026), Ultragenyx reported revenue of about $173 million, up about 8.1% year over year, and a net loss of about $118 million, or $1.16 per share, wider than the roughly $0.75 loss analysts expected. It reaffirmed 2026 revenue guidance of $730 million to $760 million, announced a 20% headcount cut and confirmed it is discontinuing GTX-102 after a failed Angelman Phase 3 trial.
How has RARE stock performed in 2026?
+
As of November 20, 2026, RARE closed near $16.54, down about 29.9% year to date and about 47% over one year, up from its 52-week low of about $12.73 but far below its high of about $39.89. Past performance does not predict future returns, and Walnut is not an investment adviser.
What happened to Ultragenyx's Angelman syndrome drug?
+
GTX-102 failed to prove efficacy in its one-year randomized Phase 3 trial in Angelman syndrome, and Ultragenyx said with its Q3 2026 results that it is discontinuing the program. The CEO attributed the miss to too much variation in the control group across multiple endpoints. The company is also ending its UX701 Wilson disease gene therapy.
Guides that feature RARE
RARE is one of the names covered in these guides. Each one puts the stock next to its peers so you can see where it fits rather than judging it alone.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Ultragenyx Pharmaceutical Inc.'s investor relations page or your broker before making investment decisions.